<code id='66403CC683'></code><style id='66403CC683'></style>
    • <acronym id='66403CC683'></acronym>
      <center id='66403CC683'><center id='66403CC683'><tfoot id='66403CC683'></tfoot></center><abbr id='66403CC683'><dir id='66403CC683'><tfoot id='66403CC683'></tfoot><noframes id='66403CC683'>

    • <optgroup id='66403CC683'><strike id='66403CC683'><sup id='66403CC683'></sup></strike><code id='66403CC683'></code></optgroup>
        1. <b id='66403CC683'><label id='66403CC683'><select id='66403CC683'><dt id='66403CC683'><span id='66403CC683'></span></dt></select></label></b><u id='66403CC683'></u>
          <i id='66403CC683'><strike id='66403CC683'><tt id='66403CC683'><pre id='66403CC683'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:196
          Miniature people figurines standing in a group looking down. -- health tech coverage from STAT
          Adobe

          In less than two years, digital health’s high-flying class of public debuts have landed with a resounding thud.

          Accelerated by the pandemic’s forced adoption of telehealth and other digital health solutions, 2021 saw more than 30 health technology startups go public, raising hundreds of millions and in some cases billions of dollars. Today, three members of the class of 2021 have gone bankrupt. Twelve companies have lost more than 90% of their initial value, including Bright Health Group, Cue Health, and Better Therapeutics. And dangerously low reserves have inspired desperate moves to slash costs, drum up liquidity, and find buyers.

          advertisement

          Most recently, the bankruptcy of digital primary care company Babylon Health has drawn attention to the plight of newly-public health tech companies, and how the froth of dealmaking at the height of the pandemic led to overblown valuations. Before its debut in June 2021, Babylon was valued at $4.2 billion; after filing for bankruptcy in August, its U.K. telemedicine business was sold for just over $600,000.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          JPM: CVS says Medicare Advantage patients are impacting profits
          JPM: CVS says Medicare Advantage patients are impacting profits

          WilfredoLee/APMedicareAdvantagememberscontinuetogotothedoctorandgethealthcareproceduresalotmorethanp

          read more
          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more

          Antibiotic resistance and the global rise in human conflict

          ApatientwithcrutcheswalkpasttheskeletonofahospitaldestroyedbyaRussianattack.EvgeniyMaloletka/APInrec